Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Conceptus: Birth control device developer's plans for a secondary offering of 4 mil. shares of common stock are outlined in a recent filing with the Securities and Exchange Commission. The filing precedes a scheduled July 22-23 FDA Obstetrics & Gynecology Devices Panel meeting to review data on 400 patients treated with the Essure non-incisional, permanent birth control system, which has been granted fast-track status (1"The Gray Sheet" May 27, 2002, In Brief). The implant is expected to debut in the U.S. next year as an alternative to surgical tubal ligation and vasectomy, which currently account for about 1 mil. procedures annually. All of the shares will be offered by the company with UBS Warburg acting as the sole book-running manager. CIBC World Markets, Adams Harkness & Hill and SG Cowen are acting as co-managers...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT016688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel